Author name: Claritas Rx

The Food and Drug Administration (FDA) has recently been the center of attention in the biopharmaceutical world, pushing for a notable shift in the discourse surrounding biosimilars. The federal agency has openly campaigned for the abolition of ‘interchangeability‘ – a term it perceives as causing more confusion than clarity and adversely impacting the market penetration […]

The United States is currently experiencing an unsettling wave of drug shortages, as reported by the American Society of Health-System Pharmacists (ASHP). This ongoing crisis is putting the flexibility and robustness of our healthcare system to the test amid an unparalleled rise in medication shortages. According to the ASHP report, the first three months of

In the realm of healthcare, the patient journey stands as a fundamental framework, guiding the interaction between patients, healthcare providers, and the wider health ecosystem. But within the vast spectrum of patient care, not all journeys are equal. Some are marked by urgency, the relentless pursuit of health, and the stark realities of a life

As we step further into the fray and journey into the world of healthcare, one startling revelation makes itself known – cost-related medication non-adherence is a reality that 1 in 6 US patients diagnosed with Chronic Obstructive Pulmonary Disease (COPD) have to deal with, according to a recent article published by The American Journal of

In the dynamic terrain of the biopharmaceutical industry, patient services have surfaced as a pivotal differentiator for manufacturers. With an increased emphasis on patient-centric care, pharma manufacturers are rethinking ways to extend beyond mere provision of medication. Today’s patients seek holistic support; they demand comprehensive service programs that guide them through the intricate healthcare labyrinth

The field of cell and gene therapy is rapidly transforming today’s treatment landscape for complicated cases like rare diseases. Simon Alfano, Alex Gorham, Alberto Loche, and Pablo Salazar report that biopharmaceutical companies are working diligently to develop new, life-saving products, with over 50 new cell and gene therapies launched in 2024, in an article on McKinsey & Company.

In the complex world of modern healthcare, nestled amid the clinical jargon, the labyrinth of insurance structures, and the pharmaceutical industry, lies a process known as step therapy. Step therapy, often a misunderstood and contentious subject, is a treatment approval protocol that requires patients to first try and fail on one or more preferred, typically

In the intricate web of healthcare, where policy, economics, and patient care converge, rises a contentious practice known as step therapy. Often lauded by insurers for its cost-controlling prowess, step therapy sows seeds of uncertainty for many patients, forcing them to navigate a labyrinth of medications before laying claim to the treatment their doctors initially